Shots:

• The P-III A4091059 study involves assessing of tanezumab (5mg-10mg) vs PBO vs tramadol (prolonged release) in 1-832 in the ratio 2:2:2:3 with moderate-to-severe chronic low back pain (CLBP) in North America- EU and Asia for 56 wks.
• The P-III A4091059 study results: well tolerated @56wks.; RPOA (1.4% vs 0.1%); ratio of RPOA type 1 (accelerated joint space narrowing) RPOA type 2 (damage or deterioration of the joint)- 6:1; Subchondral insufficiency fracture (0.4%); total joint replacement (0.7%); no events of osteonecrosis
• Tanezumab (5mg- 10mg- SC) is a mAb- NGF inhibitor and has also received FDA’s FT designation in Jun-2017. In 2013- Pfizer and Lilly collaborated to jointly develop and commercialize tanezumab 

Ref: Pfizer | Image: Patient Daily